{"id":"W4386538802","doi":"10.1093/neuonc/noad137.005","title":"PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Temozolomide; Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Nivolumab; Oncology; Progression-free survival; Randomized controlled trial; Phases of clinical research; Dacarbazine; Surrogate endpoint; Cancer; Chemotherapy; Confidence interval; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00301071,0.0009532815,0.005811523,0.001997493,0.0002868435,0.00003187557,0.0005912114,0.0009700229,0.0005129009],"category_scores_gemma":[0.004259936,0.0008281802,0.0009537735,0.002565051,0.0006859821,0.0001772617,0.0005773584,0.001188387,0.000216032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001776264,"about_ca_system_score_gemma":0.002083801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001169586,"about_ca_topic_score_gemma":0.002247366,"domain_scores_codex":[0.9894965,0.003420332,0.003032455,0.001642046,0.0009307507,0.001477933],"domain_scores_gemma":[0.9867145,0.009723241,0.001276429,0.001307514,0.0003668774,0.0006113848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8635418,0.03411778,0.0009957092,0.00006468507,0.001172121,0.01662715,0.004400291,0.0002567836,0.04320016,0.00007020493,0.01166477,0.02388851],"study_design_scores_gemma":[0.8803274,0.08993404,0.000863514,0.00008239836,0.001623975,0.0001819222,0.001613199,0.001980692,0.01191998,0.0001174608,0.01086,0.0004954262],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764328,0.0002866918,0.000009166459,0.005295744,0.003114478,0.01239359,0.00006389167,0.0004121003,0.001991564],"genre_scores_gemma":[0.9939001,0.0006541621,0.000147612,0.001063384,0.0005692907,0.003205163,0.0001341419,0.0001635879,0.0001625321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05581626,"threshold_uncertainty_score":0.9994169,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02744413339286474,"score_gpt":0.3433068402133076,"score_spread":0.3158627068204429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}